- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00235690
Optimizing Dosing of Colistin for Infections Resistant to All Other Antibiotics, Approved NIH Protocol Dated 12.06.07(DMID Protocol #07-0036)
Pharmacokinetics and Pharmacodynamics of Intravenous Colistin- Pilot Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
At baseline (upon signing informed consent), the following information will be collected: Demographic data - age, sex, height, weight, state of birth, underlying illnesses, underlying infection, immunosuppression, antibiotic use, laboratory results, current medication use, any other prior medical problems/history and clinical outcomes.
The research coordinator will contact the patient on days 14, 28 and 90 days after the infection to determine clinical outcome. If the patient is still an inpatient the research coordinator will visit the patient in their hospital room to evaluate the patient's health status. This visit will take about 10 minutes. If the patient has been discharged from the hospital, the patient will be contacted by telephone by the research coordinator to determine the health status, if no recent electronic medical record exists. This telephone contact will take about 10 minutes.
Blood work and microbiologic samples to be collected:
Collection of six samples of 3 mL blood on the third or fourth day of colistin therapy will occur. These samples will be collected:
- immediately pre-dose,
- at the end of the colistin infusion,
- 30 minutes after the end of the colistin infusion,
- 60 minutes after the end of the colistin infusion,
- 4 hours after the end of the colistin infusion,
- 12 hours after the end of the colistin infusion (or immediately prior to the next dose if the drug is being given every 12 hours).
Indwelling venous and arterial access lines, if already in place, will be utilized for the pharmacological study's blood draws.
Rationale: The samples will be utilized for quantification of plasma levels of colistin.
Collection of microbiologic samples within 48-96 hours of the initiation of colistin therapy. These samples are two sets of blood cultures if the patient had bacteremia, a mini-BAL for quantitative bacterial culture if the patient had pneumonia and a cerebrospinal fluid collection if the patient had Gram negative meningitis and has a cerebrospinal fluid drain in situ. Additionally, these samples will be used to determine the concentrations of colistin and CMS at the site of infection. A 3mL blood sample will be taken at the same time as these specimen collections to determine concomitant serum concentrations of colistin and CMS.
Rationale: These samples will be used to determine if there has been rapid bacteriologic clearance of infection and to determine the concentrations of drug at the site of infection.
The blood samples will be processed and stored in a -80° C freezer in a secured laboratory under the supervision of the principal investigator. These samples will then be sent to the laboratory of Drs Jian Li and Roger Nation in Melbourne, Australia, to determine the amount of colistin and CMS that reached the participant's blood following dose administration. All samples will be sent de-identified.
All samples will be analyzed to obtain the amount of colistin and CMS found in the blood. The biologic samples will be under the control of the principal investigator of this research project. To protect confidentiality, all personal identifiers (i.e., name, social security number, and birth date) will be removed (de-identified) and replaced with a specific code number. The information linking these code numbers to the corresponding subjects' identities will be kept in a separate, secure location. The investigators on this study will keep the samples indefinitely. All samples sent outside of the UPMC facility will be de-identified. If a subject withdraws and provides the request in writing, samples collected and not already processed will be destroyed. All samples at UPMC will be kept in the investigator's laboratory located in Scaife Hall, Room 812, 3550 Terrace Street. All patients will be seen at the UPMC facility while they are inpatients.
Other items to be collected for study purposes:
Microbiology - the organism that caused the infection will be sub-cultured in the clinical microbiology laboratory (after the diagnosis has been obtained since the microbiology lab would otherwise destroy the culture) and provided to the investigators. All subsequent Gram negative bacterial isolates will be sub-cultured and stored for similar purposes.
An unopened vial of colistin from the same batch as used for the patient will be collected for analysis, so the actual dose of colistin can be calculated.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males or females greater than 18 years of age.
- All patients will remain in the hospital for pharmacokinetic sampling.
- All subjects must be on the medication colistin as part of their standard of care.
- All individuals approached for participation shall be able to read and comprehend English.
Exclusion Criteria: None
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: blood draws
all patients enrolled will have PK blood samples obtained around a colistin dosing
|
PK samples obtained around a clinical dosing of colistin
PK blood samples will be obtained around a clinical dosing of colistin
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To provide pharmacokinetic data on intravenous (IV) CMS/colistin
Time Frame: 5 years
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Determine if CMS/colistin dosing is suboptimal in ill patients
Time Frame: 5 years
|
5 years
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB# 0509011
- NIH (NIH U19 AI 90023)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bacteremia
-
Armata Pharmaceuticals, Inc.United States Department of DefenseRecruitingBacteremia | Staphylococcus Aureus | Staphylococcus Aureus Bacteremia | Bacteremia Due to Staphylococcus Aureus | Bacteremia StaphUnited States, Australia
-
Osijek University HospitalCompletedSepsis | Gram-negative Bacteremia | Gram-Positive BacteremiaCroatia
-
Rabin Medical CenterCompletedGram Negative BacteremiaIsrael, Italy
-
Duke UniversityMerck Sharp & Dohme LLCCompletedBacteremia | Gram-negative BacteremiaUnited States
-
The First Affiliated Hospital of Xinxiang Medical...RecruitingSalmonella BacteremiaChina
-
Fundación Pública Andaluza para la gestión de la...Spanish Clinical Research Network - SCReN; Spanish Network for Research in...RecruitingEnterococcal BacteremiaSpain
-
LegoChem Biosciences, IncRecruitingMRSA BacteremiaKorea, Republic of
-
The University of Texas Health Science Center,...RecruitingEnterococcal BacteremiaUnited States, Germany, Spain, Argentina, Chile
-
Aimee LiCompleted
-
Singapore General HospitalSingapore Clinical Research InstituteTerminatedBacteremia Due to Staphylococcus AureusSingapore
Clinical Trials on Blood draws
-
IRCCS Policlinico S. DonatoRecruitingCoronary SyndromeItaly
-
Hospices Civils de LyonRecruitingMelanoma | B-cell Lymphoma | Cancer | Breast Cancer | Head and Neck Cancer | Glioblastoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Bladder Cancer | Endometrial Cancer | Renal Cancer | Hepatocellular CancerFrance
-
University of FloridaActive, not recruitingSepsis | Altered Mental Status | Sepsis-Associated Delirium | Sepsis Associated Encephalopathy | Delirium, Sepsis AssociatedUnited States
-
University College CorkRoyal College of Surgeons, IrelandTerminatedCoronary Artery DiseaseIreland
-
Children's Mercy Hospital Kansas CityWithdrawn
-
University of South AlabamaUnknown
-
Women and Infants Hospital of Rhode IslandAbbottUnknown
-
Xinhua Hospital, Shanghai Jiao Tong University...Shanghai Shen Kang Hospital Development CenterUnknownProstatic Neoplasms | Prostatic AdenomaChina
-
Harvard School of Public Health (HSPH)CompletedHIV Infections | Respiratory Tract Diseases | SepsisBotswana
-
Medical University of South CarolinaCompletedSolid Tumor, AdultUnited States